Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
You may also be interested in...
With Nurtec and zavegepant in hand from Bristol, Biohaven tries for another success with a spinal muscular atrophy asset. It will move into epilepsy indications with the buyout of Channel, a subsidiary of Knopp.
Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.